Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 17, 2009

Premium

Regulus Therapeutics, the microRNA drugs joint venture of Alnylam Pharmaceuticals and Isis Pharmaceuticals, has named Hubert Chen as its vice president of translational medicine.

In the role, Chen will be "responsible for leading the translation of the important biological discoveries in the field of microRNA therapeutics into new medicines," Regulus said.

Before joining Regulus, Chen was senior director of clinical research at Amylin Pharmaceuticals. Before that, he was associate director of medical sciences at Amgen.

He holds an MD from Columbia University and a BAS in political sciences and biological sciences from Stanford University.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.